Litcius/Paper detail

Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920

Mitchell Machtay, Pedro A. Torres‐Saavedra, Wade L. Thorstad, Phuc Félix Nguyen‐Tan, Lillian L. Siu, F. Christopher Holsinger, Adel K. El‐Naggar, Christine H. Chung, Jennifer A. Dorth, N.Y. Lee, Jason W. Chan, Neal Dunlap, Voichita Bar Ad, William Stokes, Arnab Chakravarti, David J. Sher, Shyam Rao, Jonathan Harris, Sue S. Yom, Quynh‐Thu Le

2023International Journal of Radiation Oncology*Biology*Physics10 citationsDOI

Topics & Concepts

MedicineCetuximabClinical endpointHead and neck cancerHazard ratioInternal medicineRandomized controlled trialOncologyRadiation therapyExact testHead and neck squamous-cell carcinomaToxicityLog-rank testConfidence intervalCancerSurvival analysisColorectal cancerHead and Neck Cancer StudiesCancer Diagnosis and TreatmentCholangiocarcinoma and Gallbladder Cancer Studies
Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920 | Litcius